|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Joensuu H et al. Significant improvement in recurrence-free survival (RFS) when
capecitabine (X) is integrated into docetaxel (T) 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): Interim analysis of the FinXX-trial. San Antonio Breast Cancer Symposium 2008;Abstract 82.
Johnston S et al. Lapatinib combined with letrozole vs letrozole alone for front line
postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC):
First results from the EGF30008 trial. Presentation. San Antonio Breast Cancer Symposium 2008;Abstract 46.
O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with
trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on
trastuzumab therapy. Proc ASCO 2008;Abstract 1015.
Storniolo AM et al. Phase I dose escalation and pharmacokinetic study of lapatinib in
combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008;26(20):3317-23. Abstract
Von Minckwitz G et al. Capecitabine vs capecitabine + trastuzumab in patients with
HER2-positive metastatic breast cancer progressing during trastuzumab treatment:
The TBP phase III study (GBG 26/BIG 3-05). Proc ASCO 2008;Abstract 1025.
 |
 |
EDITOR
Neil Love, MD
Harold J Burstein, MD, PhD
- Select publications
Jack Cuzick, PhD
- Select publications
Howard A Burris III, MD
- Select publications
Mark D Pegram, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
